Glaxosmithkline Pharmaceuticals Ltd logo

Glaxosmithkline Pharmaceuticals Ltd

GLAXO NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹45,689 Cr
Volatility
Moderate
P/E Ratio
45.64
EBITDA
₹1,455 Cr
Return on Equity
45.69%
Debt to Equity
0.01
Book Value
₹133.85
EPS
₹45.47
52W High
₹2,883.4
52W Low
₹2,088.1

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Glaxosmithkline Pharmaceuticals Ltd insights

40 extracted metrics + investor summaries across FY13–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
  • Company has been maintaining a healthy dividend payout of 94.6%

Weaknesses

2
  • Stock is trading at 20.2 times its book value
  • The company has delivered a poor sales growth of 5.49% over past five years.

Growth Rate

Revenue Growth
1.85% ↗
Net Income Growth
11.69% ↗
Cash Flow Change
-29.97% ↘
ROE
-3.89% ↗
ROCE
-3.30% ↗
EBITDA Margin (Avg.)
7.95% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

GlaxoSmithKline Pharmaceuticals Ltd is a debt-free healthcare company with a market cap of ₹44,518 Cr, trading at a PE of 41.5x and a PB of 19.57x. The company delivers strong return on equity (46% last year, 43% 3-year average) and maintains a 94.6% dividend payout, but revenue growth has been subdued at 5% CAGR over five years with the stock declining 6% over the past one year.

Bull Case 8
  • Company is virtually debt-free, providing strong balance sheet resilience and financial flexibility in an uncertain macro environment
  • Exceptional return on equity at 46% last year and a 3-year average ROE of 43%, indicating highly efficient capital deployment
  • 10-year ROE of 33% demonstrates sustained long-term profitability well above the cost of equity
  • Healthy dividend payout of 94.6% with a current dividend yield of 2.18%, offering consistent income to shareholders
  • Compounded profit growth of 18% over 3 years and 15% over 5 years, significantly outpacing revenue growth and reflecting operating leverage
  • TTM profit growth of 11% continues to outpace TTM sales growth of 6%, suggesting margin expansion is ongoing
  • Backed by the global GSK parentage, providing access to a strong pipeline of patented and specialty pharmaceutical products
  • 3-year stock CAGR of 23% reflects meaningful long-term wealth creation despite recent short-term weakness
Bear Case 8
  • Stock trades at 19.57x book value, a steep valuation premium that leaves little margin of safety for investors
  • Compounded sales growth of only 5% over 5 years and 3% over 10 years signals structurally low top-line momentum
  • PE ratio of 41.5x is elevated for a company growing revenue at just 6% TTM, implying a high PEG ratio
  • Stock has declined 6% over the past 1 year, underperforming broader market indices during the same period
  • 10-year stock CAGR of only 5% suggests the stock has been a long-term underperformer relative to benchmarks
  • 94.6% dividend payout leaves minimal retained earnings for reinvestment in growth initiatives or R&D
  • TTM revenue growth of 6% shows no material acceleration from the 5-year average, indicating limited growth catalysts
  • As a subsidiary of a global MNC, strategic decisions including product launches and pricing remain dependent on the parent company's priorities for India

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 18h ago
Positives 2
  • PAT surges 24% in Q1FY27 Aug 6

    GSK India reported PAT of ₹253.33 crore (up 24%) and revenue of ₹924.42 crore (up 15%) in Q1FY27, driven by strong General Medicines brands and traction in Shingrix and oncology therapies.

  • ₹52 Cr tax refund received Aug 6

    GSK received a ₹52.00 crore tax refund for AY 1984-85 on August 6, 2026, along with ₹42.09 crore in interest income from the refund.

Neutral 2
  • Shareholder nod for MD reappointment Aug 13

    GSK India issued a postal ballot for re-appointment of Bhushan Akshikar as MD and appointment of Karine Natland as Non-Executive Director.

  • Analyst meet held on Aug 3 Aug 3

    GSK Pharma hosted a digital analyst and institutional investor meeting on August 3, 2026, and subsequently uploaded audio recordings per SEBI regulations.

TL;DR: GSK India is executing well with strong Q1FY27 earnings growth of 24% PAT and 15% revenue, supported by both legacy brands and newer innovative assets like Shingrix. The ₹52 crore tax refund adds a one-time boost. No visible headwinds emerged in the recent news cycle. The trend is positive with portfolio transformation gaining momentum, though sustainability of double-digit growth will depend on continued traction in specialty therapies.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
762
957
805
930
815
1,011
949
974
805
980
1,041
995
938
Expenses
618
668
587
673
584
689
658
641
554
644
670
644
643
Operating Profit
144
289
218
257
231
322
292
333
251
336
371
351
296
OPM %
19%
30%
27%
28%
28%
32%
31%
34%
31%
34%
36%
35%
31%
Other Income
54
28
-135
32
36
39
35
41
44
36
50
36
44
Interest
0
0
0
1
0
0
0
1
0
1
1
1
1
Depreciation
16
18
17
18
16
17
19
15
16
17
20
13
16
PBT
181
299
65
271
249
344
308
359
279
354
400
373
322
Tax %
27%
27%
30%
28%
27%
27%
25%
27%
27%
27%
26%
26%
26%
Net Profit
132
218
46
194
182
252
230
263
205
257
296
278
237
EPS in Rs
7.81
12.84
2.7
11.48
10.76
14.91
13.57
15.52
12.1
15.2
17.45
16.4
14
Figures in ₹ Crores

Profit & Loss

  Mar 2015 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,305
2,838
2,908
2,871
3,128
3,224
2,926
3,278
3,252
3,454
3,749
3,822
3,955
Expenses
2,672
2,360
2,489
2,363
2,527
2,567
2,327
2,516
2,447
2,545
2,570
2,512
2,601
Operating Profit
633
478
420
508
601
657
598
762
804
909
1,179
1,309
1,354
OPM %
19%
17%
14%
18%
19%
20%
20%
23%
25%
26%
31%
34%
34%
Other Income
149
125
119
70
131
-262
9
1,401
103
-21
149
166
166
Interest
0
0
0
0
1
6
4
2
2
2
1
3
3
Depreciation
25
25
27
38
49
83
79
68
66
70
67
66
67
PBT
756
578
511
540
683
306
525
2,093
839
816
1,260
1,406
1,449
Tax %
37%
35%
34%
35%
35%
70%
32%
19%
27%
28%
26%
26%
—
Net Profit
476
376
337
351
445
93
358
1,695
611
590
928
1,036
1,068
EPS in Rs
28.12
22.2
19.88
20.7
26.29
5.5
21.14
100
36.05
34.83
54.75
61.15
63.05
Div. Payout %
111%
113%
75%
85%
76%
727%
142%
90%
89%
92%
99%
93%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
85
85
85
169
169
169
169
169
169
169
169
Reserves
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
1,782
2,098
Borrowings
3
2
2
1
1
0
35
20
16
19
10
33
Other Liabilities
1,384
869
995
1,889
1,771
1,315
1,602
1,950
1,570
1,760
2,147
2,023
Total Liabilities
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
Fixed Assets
123
204
258
325
432
758
387
331
330
321
284
281
CWIP
115
268
605
923
1,003
120
13
30
20
14
14
33
Investments
0
6
0
0
0
0
0
366
518
813
1,118
1,392
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
2,692
2,618
Total Assets
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
338
139
234
473
409
490
578
811
484
582
1,290
903
Investing
180
499
301
-104
-153
-57
418
-406
808
9
-46
397
Financing
-497
-638
-511
-307
-358
-428
-696
-524
-1,543
-562
-769
-737
Net Cash Flow
21
0
24
62
-102
6
300
-119
-251
29
475
563
Free Cash Flow
175
-69
-24
639
166
336
536
2,371
451
573
1,273
870
CFO/OP
93
72
94
133
101
103
121
122
93
92
116
93
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
11
16
21
19
14
11
27
23
22
23
28
26
Inventory Days
91
156
111
147
131
135
159
144
131
144
126
124
Days Payable
74
97
73
149
109
100
135
156
122
171
186
154
Cash Conversion Cycle
27
75
60
17
36
46
50
11
31
-4
-31
-4
Working Capital Days
-48
26
7
-90
-72
-38
-39
-94
-57
-64
-99
-91
ROCE %
42%
29%
22%
26%
31%
33%
38%
37%
36%
51%
63%
61%

Shareholding Pattern

As of Jun 2026
Promoters 75.00%
Public 10.21%
DIIs 7.80%
FIIs 4.79%
Others 2.20%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
3.48%
4.02%
4.36%
4.50%
4.52%
4.89%
4.80%
4.64%
4.62%
4.79%
DIIs
5.31%
5.51%
5.50%
5.61%
5.61%
4.08%
10.45%
10.28%
10.30%
10.23%
10.01%
8.53%
7.90%
7.50%
7.34%
7.30%
7.79%
7.70%
7.75%
7.70%
7.68%
7.80%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
11.02%
10.86%
10.83%
10.67%
10.41%
10.41%
10.40%
10.56%
10.54%
10.57%
10.62%
11.08%
11.27%
11.15%
10.97%
10.96%
10.60%
10.32%
10.34%
10.36%
10.35%
10.21%
Others
8.67%
8.62%
8.67%
8.73%
8.98%
10.51%
4.15%
4.16%
4.16%
4.20%
4.37%
5.38%
2.35%
2.33%
2.33%
2.23%
2.09%
2.09%
2.11%
2.30%
2.35%
2.20%
No. of Shareholders
1,19,951
1,20,476
1,21,445
1,23,480
1,10,141
1,12,964
1,16,651
1,20,127
1,20,415
1,19,032
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885
1,23,629
1,22,904
1,22,460
1,21,763
1,26,087

Documents

Frequently Asked Questions about Glaxosmithkline Pharmaceuticals Ltd

What does Glaxosmithkline Pharmaceuticals Ltd do?
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Where is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) listed?
Glaxosmithkline Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: GLAXO and BSE: 500660. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
Glaxosmithkline Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has a market capitalisation of approximately ₹45688.81 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd is 45.64. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?
Over the past 52 weeks, Glaxosmithkline Pharmaceuticals Ltd has traded between a low of ₹2,088.1 and a high of ₹2,883.4. This range helps investors understand the stock's price volatility and recent trading levels.
Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?
Yes, Glaxosmithkline Pharmaceuticals Ltd has a dividend yield of 2.11%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has a Return on Equity (ROE) of 45.69%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Glaxosmithkline Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Glaxosmithkline Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Website gsk-india.com
CEO Mr. Bhushan Akshikar
Employees 3,113
Listed 2000-12-15
Face Value ₹ 10
Issued Size 16,94,06,034

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List